Phaseline

Targets › E4ORF1

E4ORF1: drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 1; Gastroenterology; next expected readout Dec 2026.

Open in Phaseline: the race on E4ORF1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Weill Medical College of Cornell UniversityE-CEL UVEC cells (AB-207)
Allogeneic pro-survival gene-transduced human umbilical vein endothelial cells
E4ORF1Phase 1Chronic Anal Fissure; Anal FistulaDec 2026

Conditions

Chronic Anal Fissure (1) Anal Fistula (1)

Modalities

other (1)

Companies

Weill Medical College of Cornell University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.